The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
暂无分享,去创建一个
[1] D. Campos,et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] P. Dombernowsky,et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Howell,et al. Significantly improved survival with 'arimldex' (anastrozole (A)) compared with megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC): Updated results of two randomised trials , 1997 .
[4] J. Nortier,et al. A phase III trial comparing vorozole (RIVIZOR™) versus aminoglutethimlde in the treatment of advanced postmenopausal breast cancer , 1997 .
[5] P. Lønning,et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. , 1996, British Journal of Cancer.
[6] W. Jonat. Results of phase II and phase III trials with new aromatase inhibitors , 1996 .
[7] A. Howell,et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. , 1996, European journal of cancer.